Japan’s Regulatory Evolution: Enabling Early Market Entry for Global Pharma

• Streamlined and predictable entry: Japan ensures clear timeline for regulatory and pricing review, providing emerging biopharma with a highly predictability from approval application to revenue.
• Immediate, nationwide scale in a top-tier market: Once NHI pricing is granted, companies gain access to the entire country without regional reimbursement battles—crucially, in what is effectively the fourth-largest pharmaceutical market.
• High-value environment for innovation: Japan continues to reward differentiated therapies with stable reimbursement and strong demand, making it a particularly attractive market for biotechs looking to translate cutting-edge science into durable commercial value.

This in-person event is perfect for anyone curious about the future of biotech in Japan. Network, learn, and get the inside scoop on what’s changing and why it matters!

AGENDA

9:30 Welcome: Kate Gunning, (Managing Partner, Focus Academy)

9:35-9:40 Opening Remarks: Avanish Mishra (Principal Advisor (Japan), Ishitaan Ventures)

Meeting Briefing:

Akihiro Ishiguro (Head, PMDA D.C. Office) or Koki Fukuhara (Senior Technical Officer, PMDA D.C Office)

9:40-10:00 Expert Keynotes:

The Characteristics of Pharmaceutical Regulation and Attractiveness of Developing Innovative Medical Products in Japan

Akihiro Ishiguro and Koki Fukuhara

10:00-11:30 Q & A Session and Panel Discussions:

Panelists

Avanish Mishra, Akihiro Ishiguro, Koki Fukuhara, Geetha Rao (CEO, Springborne Life Sciences), Nicola Wall (CEO, Afortiori Bio)

Closing Remarks

Akihiro Ishiguro

Know what’s Happening Next — before everyone else does.

Get App

Host or Publisher Focus Academy LLC